GMP News and Research

RSS

MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines

MRM Health, a clinical-stage biotech developing microbiome-based therapies for immune-mediated diseases, and Biocodex, an independent French pharmaceutical company with more than 70 years of experience in the microbiome field, today announced the launch of a strategic partnership to establish specialized manufacturing capabilities for live biotherapeutic products.

6 Nov 2026

Adalvo expands biosimilars portfolio through acquisition of romiplostim biosimilar program from Enzene

Adalvo today announced the acquisition of a romiplostim biosimilar program referencing Nplate® from Enzene, strengthening its biosimilars portfolio and accelerating the company’s expansion into complex biological medicines.

From Adalvo 28 Oct 2026

Prolific announces major new investments and partnerships with NantWorks and Zylidac Bio CDMO

On the heels of our exciting major investment and Nantworks partnership announcement last week, Prolific Machines is pleased to announce a great new partnership with Zylidac Bio, a fully integrated biologics CDMO located next door to us in San Francisco Bay Area, to scale up the production of Prolific's Optogentics-enabled cell lines for clinical and GMP manufacturing!

From Prolific Machines, Inc. 28 Oct 2026

New research center aims to accelerate hepatitis C vaccine development

The shifty hepatitis C virus (HCV) has a knack for outmaneuvering the immune system. Its secret is an especially high mutation rate, which has generated an abundance of viral variants with extreme genetic diversity.

27 Oct 2026

Zylidac Bio and Prolific Machines partner to scale Prolific’s next-generation biologics manufacturing platform to GMP production

Zylidac Bio, a fully integrated biologics CDMO within the Zydus Lifesciences Limited (Zydus) group, and Prolific Machines, a biotechnology company advancing biologics development and manufacturing through integrated optogenetics-enabled solutions delivering breakthrough yields, superior on-target quality, and precise process control, today announced a partnership to scale Prolific's platform from early development through GMP production.

From Zylidac Bio LLC 22 Oct 2026

Stem cell therapies may need new protein quality control standards

Current Good Manufacturing Practice (GMP) standards for cell therapies assess identity, viability, sterility, and genetic stability. For extracellular vesicle (EV) products, Minimal Information for Studies of Extracellular Vesicles (MISEV2023) guidance adds particle size, concentration, markers, morphology, contaminants, endotoxin, and assays.

22 Oct 2026

All-in-one solution for continuous microbial monitoring without production interruptions

Particle Measuring Systems (PMS), a global leader in contamination monitoring solutions, today announced the launch of the BioCapt® Single-Use STS Microbial Monitor, a sterile transfer solution that enables the introduction of viable air monitoring consumables into isolators and Restricted Access Barrier Systems (RABS) without requiring additional decontamination activities.

From Particle Measuring Systems 21 Oct 2026

Touchlight announces leadership transition, with Will Downie appointed interim CEO

Touchlight today announces that Karen Fallen is stepping down as CEO and that the Board of Directors has appointed Will Downie as Interim Chief Executive Officer.

From Touchlight 21 Oct 2026

Scientists discover immune pathway behind radiation-induced lung damage

Researchers at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the country, have uncovered an immune pathway that may contribute to radiation-related lung damage and have identified a potential strategy to block it.

20 Oct 2026

S2N.Bio commences technology transfer of Alzheimer’s cell therapy to Cell Therapies’ Melbourne GMP facility

Cell Therapies Pty Ltd and S2N.Bio (“S2N”) have commenced technology transfer of S2N’s cell therapy candidate for Alzheimer’s disease. The transfer will enable GMP manufacture of clinical trial material for S2N’s first-in-human study in Australia.

20 Oct 2026

Could this flowering plant help people lose body fat?

Lythrum salicaria extract supplementation led to body fat reduction in a clinical trial, suggesting a promising plant-based approach to weight management.

19 Oct 2026

Developing biomaterials for soft tissue reconstruction

Explore how biomaterials and additive manufacturing support medical device development for soft tissue reconstruction.

From Thermo Fisher Scientific – Pharmaceutical and Biopharmaceutical Solutions 13 Oct 2026

Bio-Techne expands global GMP manufacturing network with new Bristol facility to advance scalable cell therapy development

Bio-Techne Corporation, a global provider of life science tools, reagents and diagnostic products, today announced the opening of a new manufacturing facility for Good Manufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom, further expanding the company's global capabilities to support the rapidly growing cell therapy market.

From Bio-Techne 8 Oct 2026

Forge Nano and Nanexa enter joint development agreement to advance manufacturing for ALD-coated PharmaShell® long-acting injectable medicines

Forge Nano, Inc., a leading U.S.-based semiconductor equipment and advanced materials company pioneering Atomic Layer Deposition ("ALD") technology for artificial intelligence ("AI")-era chip manufacturing and defense battery applications, which has signed an agreement to merge with Archimedes Tech SPAC Partners II Co. ("Archimedes II"), today announced a Joint Development Agreement ("JDA") with Nanexa AB to develop scalable pharmaceutical manufacturing capabilities for Nanexa's PharmaShell® drug delivery platform and its portfolio of proprietary and partnered programs.

From Forge Nano 23 Sep 2026

ACROBiosystems deepens its France presence with a dedicated hub at The HIVE Innovation Center, embedding into the Campus Grand Parc ecosystem

Kadans Science Partner is pleased to welcome ACROBiosystems to The HIVE Innovation Center, its laboratory and office building dedicated to the life sciences, situated on the Campus Grand Parc in Villejuif.

From ACROBiosystems 16 Sep 2026

Multiple sclerosis treatment approach developed at Mainz University moves toward clinical application

A therapeutic approach pioneered in Mainz for the treatment of multiple sclerosis (MS) is taking an important step toward clinical application.

1 Sep 2026

African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials

Leading African biopharmaceutical company Minapharm Group, headquartered in Egypt with subsidiaries in Berlin, will receive up to US$16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate, strengthening efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on record affecting the Democratic Republic of the Congo (DRC).

28 Aug 2026

New review urges proteostatic fitness standards for stem cell therapies

Stem cell therapies have expanded rapidly, with more than 115 clinical trials involving over 1,200 patients approved by late 2024. The U.S. Food and Drug Administration (FDA) recently approved Ryoncil (remestemcel‑L) for children with steroid‑refractory acute graft‑versus‑host disease, signaling a major shift toward routine clinical use.

11 Aug 2026

Integrated nanomaterials offer new strategies for cancer immunotherapy

Immune checkpoint inhibitors, cancer vaccines and cellular therapies have reshaped oncology, yet most patients still do not achieve lasting benefit.

9 Aug 2026

Sino Biological launches SuperNuclease® Pro with free trial program

Sino Biological, Inc., a global leader in recombinant technology, announced the launch of SuperNuclease® Pro (Cat#: SSNP02).

From Sino Biological Inc. 31 Jul 2026